Skip to main content
Top
Gepubliceerd in: Netherlands Heart Journal 6/2016

Open Access 12-05-2016 | Editorial Comment

Pulmonary hypertension in the changing landscape of congenital heart disease: Global differences and a possible driver of end-stage heart failure

Auteurs: A. Van De Bruaene, W. Budts

Gepubliceerd in: Netherlands Heart Journal | Uitgave 6/2016

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
insite
ZOEKEN
In this issue of the Netherlands Heart Journal, the articles of Van Riel et al. and Couperus et al. focus on some of the questions encountered in contemporary clinical congenital cardiology practice [1, 2].
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is rare, with an estimated prevalence between 1.6 and 12.5 cases per million adults [3]. Registries have provided important information on the epidemiology and clinical phenotype of patients with PAH-CHD [46], but have often been limited to a Western, white patient population, limiting comparison between population demographics and healthcare delivery systems. The article by Van Riel et al. provides valuable new information [2]. They showed that despite having worse exercise performance at baseline, Singaporean patients not only had similar improvement on exercise capacity, but even better survival when compared with their Dutch counterparts. Age at initiation of disease-targeting therapy (either phosphodiesterase-type-5 inhibitors, endothelin receptor antagonists, or a combination) was the strongest predictor of treatment efficacy and outcome [2].
Although the authors subsequently state that early initiation of (combination) disease-targeting therapy is important for outcome, which is probably correct and supported by other studies [7, 8], the observed difference may also reflect a changing phenotype of the patient with PAH-CHD. Increased awareness, better screening tools and an ageing population have shifted demographics in idiopathic PAH registries from a younger, predominantly female patient population in the first US National Institutes of Health (NIH) registry to an older patient population with a more equal gender distribution in more contemporary registries [911]. In contrast, registries from China still show demographics similar to the early US NIH studies [12]. Similarly, it is likely that due to improved survival of moderate and complex CHD, increased awareness for PAH, and ageing of the CHD population in Western countries, the profile of the adult PAH-CHD patient has changed. More patients will have PAH-CHD which developed after (and despite of) one or multiple surgical procedures rather than the ‘classical form’ of Eisenmenger’s syndrome due to unrepaired shunt lesions at birth [6, 13].
This change in phenotype of PAH-CHD is nicely highlighted in the article by Couperus et al. which provides a fascinating insight into the tailored treatment of some of the patients presenting with pulmonary hypertension after having had surgical repair or palliation in the past [1]. Although the current guidelines definitively provide a handhold [14], it is undeniable that some cases fall between the cracks of these guidelines. In their article, Couperus et al. describe two patients who had progressive right ventricular failure due to pulmonary hypertension (one in the presence of a recanalised central shunt with left-to-right shunting), one patient with worsening cyanosis in the setting of a hypoplastic pulmonary vasculature resulting in pulmonary hypertension with right-to-left shunting and one with pulmonary hypertension associated with increased left atrial pressure due to atrioventricular valve stenosis in the setting of a univentricular heart [1]. It is clear that all four patients had heart failure with pulmonary (arterial) hypertension being the main driver of the heart failure symptoms, but their specific cases may not be covered in detail by recently published recommendations for CHD heart failure [15]. It is also immediately clear that heart failure in adults with CHD is vastly different from ‘classic’ heart failure in the general population, developing at an earlier age (patients were 23 to 49 years of age at the time of intervention [1]), and often with an underlying ‘heart failure-inducing’ haemodynamic lesion. In such circumstances surgery or percutaneous interventions may improve heart failure, even in the setting of pulmonary hypertension. It is clear that in the future there will be a need for specialised heart failure units for adult CHD patients, with close communication and collaboration between adult CHD specialists, heart failure specialists (indication for assist device; transplantation), cardiac surgeons (indication for assist devices; transplantation; intervention), interventional cardiologists, imaging and pulmonary hypertension specialists to care for those patients with complex PAH-CHD.
Registries are crucial in order to describe the clinical phenotype and outcome of patients with PAH-CHD to extend knowledge and to serve as a base for future research hypotheses. A global approach helps to increase the number of patients studied and to understand the impact of ethnicity in PAH-CHD. A change in the phenotype of the PAH-CHD patient is reflected in a growing number of complex CHD patients with a subsequent increase in the prevalence of pulmonary hypertension. Often, rather than the prototypical Eisenmenger patient, these are heart failure patients in whom pulmonary hypertension has become the driver of their heart failure symptoms. An adult CHD specialist with understanding of the underlying cardiac anatomy, the physiology of pulmonary hypertension, and the triggers of heart failure is mandatory in the teams that participate in the care of these kinds of patients.
Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Literatuur
1.
go back to reference Couperus LE, Henkens IR, Jongbloed MRM, Hazekamp MG, Schalij MJ, Vliegen HW. Tailored circulatory intervention in adults with pulmonary hypertension due to congenital heart disease. Neth Heart J. 2016;24. doi:10.1007/s12471-016-0833-7.CrossRefPubMedPubMedCentral Couperus LE, Henkens IR, Jongbloed MRM, Hazekamp MG, Schalij MJ, Vliegen HW. Tailored circulatory intervention in adults with pulmonary hypertension due to congenital heart disease. Neth Heart J. 2016;24. doi:10.1007/s12471-016-0833-7.CrossRefPubMedPubMedCentral
2.
go back to reference Van Riel ACMJ, Schuuring MJ, Hessen ID van, et al. Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome. Neth Heart J. 2016;24. doi:10.1007/s12471-016-0820-z.CrossRefPubMedPubMedCentral Van Riel ACMJ, Schuuring MJ, Hessen ID van, et al. Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome. Neth Heart J. 2016;24. doi:10.1007/s12471-016-0820-z.CrossRefPubMedPubMedCentral
3.
go back to reference Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008;68:1049–1066.CrossRefPubMed Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008;68:1049–1066.CrossRefPubMed
4.
go back to reference Duffels MG, Engelfriet PM, Berger RM, Loon RL van, Hoendermis E, Vriend JW, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198–204.CrossRefPubMed Duffels MG, Engelfriet PM, Berger RM, Loon RL van, Hoendermis E, Vriend JW, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198–204.CrossRefPubMed
5.
go back to reference Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682–87.CrossRefPubMed Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682–87.CrossRefPubMed
6.
go back to reference Van de Bruaene A, Delcroix M, Pasquet A, et al. The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol. 2009;64:447–53.CrossRefPubMed Van de Bruaene A, Delcroix M, Pasquet A, et al. The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol. 2009;64:447–53.CrossRefPubMed
7.
go back to reference Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.CrossRefPubMed Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.CrossRefPubMed
8.
go back to reference D’Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378–82.CrossRefPubMed D’Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378–82.CrossRefPubMed
9.
go back to reference Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–23.CrossRefPubMed Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–23.CrossRefPubMed
10.
go back to reference Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079–87.CrossRefPubMed Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079–87.CrossRefPubMed
11.
go back to reference Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL. Circulation. 2010;122:164–72.CrossRefPubMed Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL. Circulation. 2010;122:164–72.CrossRefPubMed
12.
go back to reference Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373–9.CrossRefPubMed Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373–9.CrossRefPubMed
13.
go back to reference Gabriels C, Meester P De, Pasquet A, et al. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol. 2014;176:833–40.CrossRefPubMed Gabriels C, Meester P De, Pasquet A, et al. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol. 2014;176:833–40.CrossRefPubMed
14.
go back to reference Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37:67–119. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37:67–119.
15.
go back to reference Budts W, Roos-Hesselink J, Radle-Hurst T, et al. Treatment of heart failure in adult congenital heart disease: a position paper of the working group of grown-up congenital heart disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2016; doi:10.1093/eurheartj/ehv741.CrossRefPubMedPubMedCentral Budts W, Roos-Hesselink J, Radle-Hurst T, et al. Treatment of heart failure in adult congenital heart disease: a position paper of the working group of grown-up congenital heart disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2016; doi:10.1093/eurheartj/ehv741.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Pulmonary hypertension in the changing landscape of congenital heart disease: Global differences and a possible driver of end-stage heart failure
Auteurs
A. Van De Bruaene
W. Budts
Publicatiedatum
12-05-2016
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 6/2016
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-016-0844-4

Andere artikelen Uitgave 6/2016

Netherlands Heart Journal 6/2016 Naar de uitgave